RET and medullary thyroid gland carcinoma: Selpercatinib has been approved as a first-line treatment by the FDA and as a second-line treatment by the EMA for RAIR DTC in RET-fusion–positive tumors and as a first-line treatment for MTC in RET-mutated tumors by both agencies (4).